Adicet opens Phase 1 enrollment for ADI-001 in autoimmune diseases; preliminary data expected H1 2025

Adicet Bio, Inc.

Phase 1 trial now enrolling lupus nephritis (LN) patients; SLE, SSc, AAV enrollment to open Q4 2024.
FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III/IV LN.
Plan to report preliminary clinical data in LN, SLE, SSc, and AAV by first half of 2025.
Trial has three arms: LN/SLE, SSc, AAV; single dose of ADI-001 with 28-day DLT window and 24-month follow-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.